Citations

Clear

6273 citation(s) found for "To, Andrew".

SLC35A2‐CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals
Sosicka, Paulina , Agadi, Satish , Almannai, Mohammed , Bacino, Carlos A. , Barone, Rita , Burton, Jennifer, Carlston, Colleen M. , Cohen, Julie S. , Coman, David , Dipple, Katrina M. , Dorrani, Naghmeh, Dobyns, William B. , Elias, Abdallah F. , Epstein, Leon G. , Gahl, William A. , Garozzo, Domenico , Hammer, Trine Bjørg , Haven, Jaclyn, Héron, Delphine, Herzog, Matthew , Hoganson, George, Hunter, Jesse M. , Jain, Mahim , Juusola, Jane, Lakhani, Shenela , Lee, Hane , Lewis, Katherine, Mak, Christopher Chun Yu , McKnight, Dianalee , Mendelsohn, Bryce A. , Mignot, Cyril , Mirzaa, Ghayda , Mitchell, Wendy G. , Muhle, Hiltrud, Nelson, Stanley F. , Olczak, Mariusz , Palmer, Christina G.S. , Partikian, Arthur , Pierson, Tyler Mark , Regan, Brigid M. , Sacoto, María J. Guillen , Scaglia, Fernando , Scheffer, Ingrid E. , Segal, Devorah , Singhal, Nilika S. , Striano, Pasquale, Sturiale, Luisa , Symonds, Joseph D. , Willis, Mary , Wolfe, Lynne A. , Yano, Shoji , Powis, Zöe , Suchy, Sharon F., Edmondson, Andrew C. , Grünewald, Stephanie , Longo, Nicola , Mak, Christopher C Y , Patterson, Marc C. , Ross, M Elizabeth , Scheffer, Ingrid E , Symonds, Joseph , Edmondson, Andrew C , Ng, Bobby G. , Botto, Lorenzo D. , Chung, Hon-Yin B , Juusola, Jane , Lee, Joy Li-Yueh , Lewis, Katherine, Lourenco, Charles , Quinonez, Shane C. , Tang, Sha , Vilain, Eric J. N. , Yang, Hui , Rosenfeld, Jill A. , Freeze, Hudson H.

Mayo Clinic

Human Mutation | February 28, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/humu.23731 | PMID 30817854 Get It

Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study
Wang, Sophia , Sarangi, Vivekananda , Link, Brian K. , Inwards, David J. , Witzig, Thomas E. , Rothman, Nathaniel , Asmann, Yan W. , Witzig, T.E. , Asmann, Yan, Cerhan, James R , Link, Brian K , Wang, Sophia S , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Feldman, Andrew L. , Cozen, Wendy , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | February 28, 2019 | Volume: 94 | Issue: 6 | Pages: No page available

10.1002/ajh.25451 | PMID 30815899 Get It

Preadmission Corticosteroid Therapy and the Risk of Respiratory Failure in Adults Without HIV Presenting With Pneumocystis Pneumonia
Wieruszewski, Patrick M. , Frazee, Erin N. , Barreto, Jason N. , Yadav, Hemang , Tosh, Pritish K. , Mara, Kristin C. , Mara, Kristin C , Wieruszewski, Patrick M , Limper, Andrew H.

Mayo Clinic

Journal of Intensive Care Medicine | February 28, 2019 | Volume: 35 | Issue: 12 | Pages: 1465-1470

10.1177/0885066619834242 | PMID 30813829 Get It

Background: Corticosteroid therapy is a well-recognized risk factor for Pneumocystis pneumonia (PCP); however, it has also been proposed as an adjunct to decrease inflammation and respiratory failure. Objective: To determine the association between preadmission corticosteroid use and risk of moderate-to-severe respiratory failure at the time of PCP presentation. Methods: This retrospective cohort study evaluated HIV-negative immunosuppressed adults diagnosed with PCP at Mayo Clinic from 2006 to 2016. Multivariable regression models were used to evaluate the association between preadmission corticosteroid exposure and moderate-to-severe respiratory failure at presentation. Results: Of the 323 patients included, 174 (54%) used preadmission corticosteroids with a median daily dosage of 20 (interquartile range: 10-40) mg of prednisone or equivalent. After adjustment for baseline demographics, preadmission corticosteroid therapy did not decrease respiratory failure at the time of PCP presentation (odds ratio: 1.23, 95% confidence interval: 0.73-2.09, P = .38). Additionally, after adjusting for inpatient corticosteroid administration, preadmission corticosteroid use did not impact the need for intensive care unit admission ( P = .98), mechanical ventilation ( P = .92), or 30-day mortality ( P = .11). Conclusions: Corticosteroid exposure before PCP presentation in immunosuppressed HIV-negative adults was not associated with a reduced risk of moderate-to-severe respiratory failure.
Energy Status and Body Composition Across a Collegiate Women’s Lacrosse Season
Zabriskie, Hannah A. , Currier, Brad S. , Harty, Patrick S. , Stecker, Richard A., Jagim, Andrew R. , Kerksick, Chad M. , Jagim, Andrew R , Kerksick, Chad M , Harty, Patrick S , Zabriskie, Hannah A , Currier, Bradley S

Mayo Clinic

Nutrients | February 25, 2019 | Volume: 11 | Issue: 2 | Pages: 470

10.3390/nu11020470 | PMID 30813399 Get It

Little data is available regarding the energy and nutritional status of female collegiate team sport athletes. Twenty female NCAA Division II lacrosse athletes (mean ± SD: 20.4 ± 1.8 years; 68.8 ± 8.9 kg; 168.4 ± 6.6 cm; 27.9 ± 3% body fat) recorded dietary intake and wore a physical activity monitor over four consecutive days at five different time points (20 days total) during one academic year. Body composition, bone health, and resting metabolic rate were assessed in conjunction with wearing the monitor during off-season, pre-season, and season-play. Body fat percentage decreased slightly during the course of this study (p = 0.037). Total daily energy expenditure (TDEE) (p < 0.001) and activity energy expenditure (AEE) (p = 0.001) energy were found to change significantly over the course of the year, with pre-season training resulting in the highest energy expenditures (TDEE: 2789 ± 391 kcal/day; AEE: 1001 ± 267 kcal/day). Caloric (2124 ± 448 kcal/day), carbohydrate (3.6 ± 1.1 g/kg), and protein (1.2 ± 0.3 g/kg) intake did not change over the course of the year (p > 0.05). Athletes self-reported a moderate negative energy balance (366–719 kcal/day) and low energy availability (22.9–30.4 kcal/kg FFM) at each measurement period throughout the study. Reported caloric and macronutrient intake was low given the recorded energy expenditure and macronutrient intake recommendations for athletes. Athletic support staff should provide athletes with appropriate fueling strategies, particularly during pre-season training, to adequately meet energy demands.
Clinical impact of intraoperative electronic health record downtime on surgical patients
Harrison, Andrew M. , Siwani, Rizwan, Pickering, Brian W. , Herasevich, Vitaly , Harrison, Andrew Marc , Herasevich, Vitaly

Mayo Clinic

Journal of the American Medical Informatics Association | February 22, 2019 | Volume: 26 | Issue: 10 | Pages: 928-933

10.1093/jamia/ocz029 | PMID 30946466 Get It

Abstract Objective Despite increased use of electronic health records (EHRs), the clinical impact of system downtime is unknown. Materials and Methods This retrospective matched cohort study evaluated the impact of EHR downtime episodes lasting more than 60 minutes over a 6-year study period. Patients age 18 years or older who underwent surgical procedures at least 60 minutes in duration with an inpatient stay exceeding 24 hours within the study period were eligible for inclusion. Out of 4115 patients exposed to 1 of 176 EHR downtime episodes, 4103 patients were matched to an unexposed cohort in a 1:1 ratio. Multivariable regression analysis, as well as trend analysis for effect of duration of downtime on outcomes, was performed. Results Downtime-exposed patients had operating room duration 1.1 times longer (p &lt; .001) and postoperative length of stay 1.04 times longer (p = .007) compared to unexposed patients. The 30-day mortality rates were similar between these groups (odds ratio 1.26, p &gt; .05). In trend analysis, there was no association between duration of downtime with respect to evaluated outcomes, postoperative length of stay, and 30-day mortality. Conclusion EHR downtime had no impact on 30-day mortality. Potential associations for increased postoperative length of stay and duration of time spent in the operating room were observed among downtime-exposed patients. No trend effect was observed with respect to duration of downtime and postoperative length of stay and 30-day mortality rates.
Temporal trends of survival and utilization of mechanical circulatory support devices in patients with in‐hospital cardiac arrest secondary to ventricular tachycardia/ventricular fibrillation
Patel, Nileshkumar, Kumar, Varun , Panakos, Andrew, Narayanan, Mahesh Anantha , Bhardwaj, Bhaskar , Arora, Shilpkumar , Deshmukh, Abhishek , Patel, Nileshkumar , Basir, Mir B. , Cohen, Mauricio G. , Kini, Annapoorna , Sharma, Samin K. , Dangas, George , O’Neill, William W. , Alfonso, Carlos E., Patel, Nileshkumar J , Atti, Varunsiri , Kumar, Varun , Anantha Narayanan, Mahesh , Patel, Nish , Basir, Mir B , Cohen, Mauricio G , Kini, Annapoorna S , Sharma, Samin K , Dangas, George

Mayo Clinic

Catheterization and Cardiovascular Interventions | February 21, 2019 | Volume: 94 | Issue: 4 | Pages: 578-587

10.1002/ccd.28138 | PMID 30790415 Get It

AbstractBackgroundPulseless ventricular tachycardia/ventricular fibrillation (VT/VF) is the initial rhythm in a third of in‐hospital cardiac arrest patients. Mechanical circulatory support (MCS) device use remains poorly understood in this population.MethodsWe conducted an observational analysis of temporal trends in the utilization of MCS in VT/VF IHCA between January 2008 and December 2014 utilizing the Nationwide Inpatient Sample (NIS) database. Using multivariable analysis, we assessed factors associated with MCS use and survival to discharge.ResultsAmong 151,628 hospitalizations with VT/VF IHCA, 14,981 (9.9%) received MCS. Intra‐aortic balloon pump (IABP) was the most commonly used MCS (9.1%). From 2008 to 2014, there was significant increase in the utilization of MCS (8.7–11%; ptrend < 0.0001). On multivariable analysis, there was 12‐fold increase and three‐fold increase in the utilization of PVAD and ECMO respectively; however, there was no significant change in the use of IABP. Over the seven‐year sample period, there was significant increase in the overall survival to hospital discharge (35.4–43.5%; ptrend < 0.0001). Survival to hospital discharge increased in both MCS and non‐MCS groups.ConclusionThere was significant increase in utilization of MCS after VT/VF IHCA during the study period. IABP was the most commonly utilized MCS. The survival to hospital discharge increased in the overall study population including both MCS and non‐MCS groups. Future studies are needed to identify patient population most likely to benefit from the use of MCS after VT/VF IHCA.
Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D
Long, Caela, Casella, Alex, O’Lear, Lauren, Caplan, Ilana, Lai, Meizan , Sasson, Issac, Makowski, Andrew J., Simmons, Rebecca A. , Levine, Michael A. , Roizen, Jeffrey D. , Singh, Ravinder J. , Levine, M A

Mayo Clinic

Journal of Bone and Mineral Research | February 21, 2019 | Volume: 34 | Issue: 6 | Pages: 1068-1073

10.1002/jbmr.3686 | PMID 30790351 Get It

ABSTRACT Normal vitamin D homeostasis is critical for optimal health; nevertheless, vitamin D deficiency is a worldwide public health problem. Vitamin D insufficiency is most commonly due to inadequate cutaneous synthesis of cholecalciferol and/or insufficient intake of vitamin D, but can also arise as a consequence of pathological states such as obesity. Serum concentrations of 25(OH)D (calcidiol) are low in obesity, and fail to increase appropriately after vitamin D supplementation. Although sequestration of vitamin D in adipose tissues or dilution of ingested or cutaneously synthesized vitamin D in the large fat mass of obese patients has been proposed to explain these findings, here we investigate the alternative mechanism that reduced capacity to convert parent vitamin D to 25(OH)D due to decreased expression of CYP2R1, the principal hepatic vitamin D 25-hydroxylase. To test this hypothesis, we isolated livers from female mice of 6 to 24 weeks of age, weaned onto either a normal chow diet or a high-fat diet, and determined the abundance of Cyp2r1 mRNA using digital droplet-quantitative PCR. We observed a significant (p &lt; 0.001) decrease in Cyp2r1 mRNA in the liver of high-fat diet–fed mice relative to lean-chow–fed female mice. Moreover, there was a significant (p &lt; 0.01) relationship between levels of Cyp2r1 mRNA and serum 25(OH)D concentrations as well as between Cyp2R1 mRNA and the ratio of circulating 25(OH)D3 to cholecalciferol (p &lt; 0.0001). Using linear regression we determined a curve with 25(OH)D3/cholecalciferol versus normalized Cyp2R1 mRNA abundance with an R2 value of 0.85. Finally, we performed ex vivo activity assays of isolated livers and found that obese mice generated significantly less 25(OH)D3 than lean mice (p &lt; 0.05). Our findings indicate that expression of CYP2R1 is reduced in obesity and accounts in part for the decreased circulating 25(OH)D. © 2019 American Society for Bone and Mineral Research.
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors
Leaf, Rebecca Karp , Ferreri, Christopher, Rangachari, Deepa, Mier, James W., Witteles, Wesley, Ansstas, George , Zubiri, Leyre , Oo, Thein Hlaing , Iberri, David , Yarchoan, Mark , Salama, April K.S. , Johnson, Douglas B. , Leavitt, Andrew D. , Rahma, Osama E. , Reynolds, Kerry L. , Leaf, David E. , Anagnostou, Theodora , Oo, Thein H , Iberri, David , Leaf, David E , Zubiri, Leyre , Yarchoan, Mark , Rangachari, Deepa , Piotrowska, Zofia

Mayo Clinic

American Journal of Hematology | February 21, 2019 | Volume: 94 | Issue: 5 | Pages: 563-574

10.1002/ajh.25448 | PMID 30790338 Get It

AbstractImmune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolutionized the treatment of cancer; however, these drugs can also cause a unique spectrum of autoimmune toxicity. Autoimmune hemolytic anemia (AIHA) is a rare, but often severe, complication of ICPis. We identified 14 patients from nine institutions across the United States who developed ICPi‐AIHA. The median interval from ICPi initiation to development of AIHA was 55 days (interquartile range [IQR], 22‐110 days). Results from the direct antiglobulin test (DAT) were available for 13 of 14 patients: 8 patients (62%) had a positive DAT and 5 (38%) had a negative DAT. The median pretreatment and nadir hemoglobin concentrations were 11.8 g/dL (IQR, 10.2‐12.9 g/dL) and 6.3 g/dL (IQR, 6.1‐8.0 g/dL), respectively. Four patients (29%) had a preexisting lymphoproliferative disorder, and two (14%) had a positive DAT prior to initiation of ICPi therapy. All patients were treated with glucocorticoids, with three requiring additional immunosuppressive therapy. Complete and partial recoveries of hemoglobin were achieved in 12 (86%) and 2 (14%) patients, respectively. Seven patients (50%) were rechallenged with ICPis, and one (14%) developed recurrent AIHA. Clinical and laboratory features of ICPi‐AIHA were similar in DAT positive and negative patients. ICPi‐AIHA shares many clinical features with primary AIHA; however, a unique aspect of ICPi‐AIHA is a high incidence of DAT negativity. Glucocorticoids are an effective first‐line treatment in the majority of patients with ICPi‐AIHA, and most patients who are rechallenged with an ICPi do not appear to develop recurrence of AIHA.
In Response
Hanson, Andrew C. , Kor, Daryl J. , Warner, Matthew A.

Mayo Clinic

Anesthesia & Analgesia | February 21, 2019 | Volume: 128 | Issue: 3 | Pages: e48-e48

10.1213/ane.0000000000003985 | PMID 30649070 Get It